Use of 3, 11b-cis-dihydrotetrabenazine in the treatment of multiple sclerosis and autoimmune myelitis

Abstract

The invention provides a compound for use in treating multiple sclerosis wherein the compound is a 3, 11b-cis-dihydrotetrabenazine of the formula (Ia): or a pharmaceutically acceptable salt thereof.

Description

The invention relates to the use of dihydrotetrabenazine in treating multiple sclerosis. Background of the invention Multiple sclerosis (MS) is a disabling neurological disorder characterized by the progressive breakdown of myelin, a protective fatty layer that surrounds nerve fibers in the central nervous system. As a result of myelin damage, these nerve fibers can no longer conduct electrical signals effectively and this produces a variety of symptoms, including changes in sensation, visual problems, muscle weakness, depression, difficulties with coordination and speech, severe fatigue, cognitive Impairment, balance problems, overheating, pain, and urinary and fecal incontinence. In more severe cases, MS can cause mobility and disability. MS is generally classified as an autoimmune disease, which results from an individual's immune system attacking the nervous system. Multiple sclerosis can be divided into three types: relapsing-remitting MS, secondary progressive MS, a...

AI Technical Summary

Problems solved by technology

Our application WO 2007 / 017643 discloses the use of 3,11b-cis-dihydrotetrafenazine as an anti-inflammatory agent but not in the treatment of multiple sclerosis

Images